Mean number of prescription fillings after 1 and 10 years of follow-up in a 5% population-based sample and a population of Danish twins, stratified on age and sex
| Type of drugs | Nelson-Aalen cumulative hazard | |||
|---|---|---|---|---|
| Age | 5% Population (n=137 300) | Twins (n=24 370) | ||
| Sex | 1 year | 10 years | 1 year | 10 years |
| All purpose | ||||
| 30–44 years | ||||
| Men | 2.5 | 28.7 | 2.2 | 25.9 |
| Women | 4.1 | 44.5 | 3.8 | 41.1 |
| 45–59 years | ||||
| Men | 3.6 | 47.4 | 3.3 | 43.1 |
| Women | 6.0 | 71.9 | 5.7 | 68.4 |
| 60+ years | ||||
| Men | 6.4 | 87.5 | 5.8 | 82.2 |
| Women | 8.3 | 105.4 | 7.2 | 95.7 |
| Circulatory system (ATC-C) | ||||
| 30–44 years | ||||
| Men | 0.1 | 3.3 | 0.1 | 2.9 |
| Women | 0.2 | 4.2 | 0.2 | 3.6 |
| 45–59 years | ||||
| Men | 0.7 | 12.6 | 0.6 | 10.6 |
| Women | 0.8 | 13.8 | 0.7 | 13.0 |
| 60+ years | ||||
| Men | 1.9 | 29.6 | 1.7 | 27.4 |
| Women | 1.9 | 30.0 | 1.6 | 26.7 |
| Nervous system (ATC-N) | ||||
| 30–44 years | ||||
| Men | 0.8 | 9.8 | 0.7 | 8.6 |
| Women | 1.1 | 14.5 | 1.0 | 13.3 |
| 45–59 years | ||||
| Men | 1.2 | 14.6 | 1.2 | 13.9 |
| Women | 2.1 | 25.0 | 2.0 | 24.1 |
| 60+ years | ||||
| Men | 1.8 | 24.4 | 1.6 | 22.2 |
| Women | 3.1 | 39.2 | 2.7 | 35.8 |
| Respiratory system (ATC-R) | ||||
| 30–44 years | ||||
| Men | 0.3 | 3.9 | 0.3 | 3.6 |
| Women | 0.6 | 6.5 | 0.5 | 5.7 |
| 45–59 years | ||||
| Men | 0.5 | 5.8 | 0.4 | 5.0 |
| Women | 0.8 | 9.8 | 0.7 | 9.1 |
| 60+ years | ||||
| Men | 1.1 | 14.4 | 0.9 | 12.5 |
| Women | 1.2 | 14.8 | 1.0 | 12.8 |
| Alimentary tract and metabolism (ATC-A) | ||||
| 30–44 years | ||||
| Men | 0.3 | 3.5 | 0.2 | 3.1 |
| Women | 0.4 | 5.0 | 0.4 | 4.1 |
| 45–59 years | ||||
| Men | 0.5 | 7.6 | 0.5 | 6.6 |
| Women | 0.7 | 9.6 | 0.7 | 8.6 |
| 60+ years | ||||
| Men | 1.1 | 15.4 | 1.1 | 15.0 |
| Women | 1.3 | 18.3 | 1.0 | 16.4 |
ATC, Anatomical Therapeutic Chemical classification system.